Tag: Novo Nordisk

Kallyope enters into drug discovery collaboration with Novo Nordisk

drug discovery
Kallyope Inc. and Novo Nordisk entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes.

Epigen Biosciences licenses kidney disease medicine to Novo Nordisk

Epigen Biosciences entered into a collaboration agreement with Novo Nordisk A/S under which Novo Nordisk has licensed the LPA1 receptor antagonist EPGN696 for development in diabetic and chronic kidney disease.

Novo Nordisk increases its ambition for stem cell-based therapies

Novo Nordisk
Novo Nordisk has licenced a technology to enable the generation of good manufacturing practice compliant human embryonic stem cell lines as well as the rights to further develop these into future regenerative medicine therapies.

Novo Nordisk will launch a new shop for insulin production in Russia

Novo Nordisk, a Danish pharmaceutical company, will launch a production facility for full-cycle manufacturing of insulin in Kaluga region. Novo Nordisk insulin plant was commissioned in the Kaluga region in 2015.

Novo Nordisk received licence for sickle cell disease drug from EpiDestiny

novo nordisk
Novo Nordisk and EpiDestiny today announced that Novo Nordisk has obtained an exclusive worldwide licence to EpiDestiny's sickle cell disease (SCD) programme, EPI01.

Ibnsina Pharma will distribute Novo Nordisk products in Egypt

ibnsina pharma egypt
Ibnsina Pharma, Egypt’s fastest-growing and second-largest pharmaceutical distributor, has signed two contracts with Novo Nordiskto distribute over 20 stock-keeping units of its products in Egypt.

Novo Nordisk obesity drug showed promising results during clinical trial

novo nordisk
Semaglutide, developed by Novo Nordisk, is an analogue of the human glucagon-like peptide (GLP-1) hormone, and induces weight loss by reducing hunger, increasing feelings of fullness and helping people eat less.

Novo Nordisk filed the approval submissions for a long-acting factor VIII

Novo Nordisk
Novo Nordisk announced the submission of a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA)

Novo Holdings started a new impact fund to combat antimicrobial resistance

antimicrobial resistance
Novo Holdings announced the launch of an impact fund with a total budget of $165 million to invest in companies involved in discovering and early-stage development of therapies to combat antimicrobial resistance.

First diabetes pill from Novo Nordisk shows solid results in clinical trials

Novo Nordisk today announced the headline results from the first phase 3a trial with oral semaglutide. First ever diabetes pill can change whole diabetes market replacing injection for blood sugar control.

Novo Nordisk received EU approval for diabetes drug

novo nordisk
Novo Nordisk announced that the European Commission (EC) has granted marketing authorisation for Ozempic (semaglutide) for the treatment of adults with type 2 diabetes.

Novo Nordisk will expand its manufacturing facility in USA

Novo Nordisk
Denmark-based Novo Nordisk, the world’s leading diabetes care company, will embark on a $65 million expansion of its diabetes product manufacturing center at its campus in North Carolina, USA

CHMP recommended marketing authorization for Novo Nordisk diabetes drug

novo nordisk
The Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending marketing authorisation for Ozempic

Russian Ministry authorizes Novo Nordisk to manufacture insulin pens

novo nordisk
The Ministry of Industry and Trade of the Russian Federation issued a license to Novo Nordisk LLC for manufacturing finished dosage forms of insulin

China Food and Drug Administration sanctioned Novo Nordisk diabetes drug

novo nordisk
Novo Nordisk today announced that the China Food and Drug Administration has approved Tresiba for the treatment of diabetes in China

Emerging research programme gets financing from Novo Nordisk

novo nordisk
The newly established research programme, ’Programme for Translational Hematology’, has just received DKK 100 million (€135000) in funding from the Novo Nordisk